

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	10/560,336 -- Conf# 2542
Filing Date	June 14, 2004
First Named Inventor	Woppmann, Claudia
Art Unit	1635
Examiner Name	Not Yet Assigned
Attorney Docket Number	APX-026.01

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
/JZ/	A	WO 02/044321	6/6/2002	Max Planck-Gesellschaft		
↓	B	WO 02/055692	7/18/2002	Ribopharma AG		
	C	WO 02/055693	7/18/2002	Ribopharma AG		
	D	WO 03/012052	2/13/2003	U.S. Govt.		
	E	WO 03/035868	5/1/2003	Ribopharma AG		
	F	WO 03/035869	5/1/2003	Ribopharma AG		
	G	WO 03/062423	7/31/2003	Ribopharma AG		
	H	WO 03/099298	12/4/2003	Max Planck-Gesellschaft		
	I	WO 04/011647	2/5/2004	Chiron Corp.		

Examiner
Signature

/Jane Zara/

Date
Considered

03/26/2009

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

2

of

2

Complete if Known

Application Number	10/560,336 -- Conf# 2542
Filing Date	June 14, 2004
First Named Inventor	Woppmann, Claudia
Art Unit	1635
Examiner Name	Not Yet Assigned
Attorney Docket Number	APX-026.01

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/JJ/	J	ELBASHIR et al. "RNA interference is mediated by 21 and 22-nucleotide RNAs" <i>Genes and Development</i> 2001 , 15, 188-200.	
↓	K	ELBASHIR et al. "Functional anatomy of siRNA for mediating efficient RNAi in <i>Drosophila melanogaster</i> embryo lysate" <i>The EMBO Journal</i> 2001 , 20(23), 6877-6888.	
	L	FUTAMI et al. "Induction of apoptosis in HeLa cells with siRNA expression vector targeted against bcl-2" <i>Nucleic Acid Research Supplement</i> 2002 , 2, 251-252.	
	M	OCKER et al. "Variants of bcl-2 specific siRNA for silencing antiapoptotic bcl-2 in pancreatic cancer" <i>Gut</i> 2005 , 54, 1298-1308.	
	N	TSUJIMOTO et al. "Human B-cell leukemia/lymphoma 2 (bcl-2) proto-oncogene mRNA encoding bcl-2-alpha protein, complete cds." Database accession no. M13994	
	O	TSUJIMOTO et al. "Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma" <i>Proc. Natl. Acad. Sci. U.S.A.</i> 1986 , 83 (14), 5214-5218.	

Examiner
Signature

/Jane Zara/

Date
Considered

03/26/2009